ReviewEye (London, England)2017
Hyper-IL-6: a potent and efficacious stimulator of RGC regeneration.
Review in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Protective Efficacy of Selenium in Cisplatin-Induced Retinal Toxicity: An Experimental Immunohistochemical and Ultrastructural Analysis.Nutrients · 2026Article
- Retrograde viral delivery of hyper-IL-6 activates Stat3 in corticospinal tract neurons but causes severe tremors and weight loss in adult mice.bioRxiv : the preprint server for biology · 2025Article
- Immunomodulation by the combination of statin and matrix-bound nanovesicle enhances optic nerve regeneration.NPJ Regenerative medicine · 2024Article
- Human microglia-derived proinflammatory cytokines facilitate human retinal ganglion cell development and regeneration.Stem cell reports · 2024Article
- Interleukin-4 protects retinal ganglion cells and promotes axon regeneration.Cell communication and signaling : CCS · 2024Article
- Interplay between mesenchymal stromal cells and the immune system after transplantation: implications for advanced cell therapy in the retina.Neural regeneration research · 2024Review
- NLRP3 and autophagy in retinal ganglion cell inflammation in age-related macular degeneration: potential therapeutic implications.International journal of ophthalmology · 2024Review
- The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.Frontiers in immunology · 2024Review
- Inhibition of microtubule detyrosination by parthenolide facilitates functional CNS axon regeneration.eLife · 2023Article
- Promotion of axon regeneration and protection on injured retinal ganglion cells by rCXCL2.Inflammation and regeneration · 2023Article
- Light damage induces inflammatory factors in mouse retina and vitreous humor.Molecular vision · 2023Article
- Axonal Regeneration: Underlying Molecular Mechanisms and Potential Therapeutic Targets.Biomedicines · 2022Review
- Silencing the enhancer of zeste homologue 2,Neural regeneration research · 2022Article
- Article
- Article
- MMP2 Modulates Inflammatory Response during Axonal Regeneration in the Murine Visual System.Cells · 2021Article
- Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice.Nature communications · 2021Article
- Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway.Development (Cambridge, England) · 2019Article
- Ciliary neurotrophic factor (CNTF) protects retinal cone and rod photoreceptors by suppressing excessive formation of the visual pigments.The Journal of biological chemistry · 2018Article
- Highly efficient transduction of primary adult CNS and PNS neurons.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mature retinal ganglion cells (RGCs) normally fail to regenerate injured axons and die soon after optic nerve injury. Research over the last two decades has demonstrated that application of IL-6-like cytokines or activation of respective downstream signaling pathways promote neuroprotection and optic nerve regeneration. However, the overall beneficial effects of natural cytokines remain usually rather moderate, possibly due to intrinsic signaling pathway inhibitors, such as PTEN or SOCS3, or a limited expression of specific cytokine receptors in RGCs. It was recently demonstrated that directly targeting the gp130 receptor, a common signalling receptor of all IL-6-like cytokines, induces stronger RGC axon regeneration in vitro and in vivo than other known growth-promoting treatments such as inflammatory stimulation or PTEN knockout. Remarkably, continuous expression of hyper-IL-6 (hIL-6) upon intravitreal AAV injection after nerve injury enables long-distance axon regeneration, with some axons growing through the optic chiasm 6 weeks after optic nerve injury. Thus, AAV-mediated hIL-6 delivery is so far one of the strongest single, post-injury treatments for the promotion of optic nerve regeneration and may be suitable for the development of novel, clinically applicable therapeutic treatments for human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.